The risk of biochemical recurrence (BCR) following radical prostatectomy for pathologic Gleason 7 prostate cancer varies according to the proportion of Gleason 4 component.
We sought to explore the value of several novel quantitative metrics of Gleason 4 disease for the prediction of BCR in men with Gleason 7 disease.
We analyzed a cohort of 2630 radical prostatectomy cases from 1990-2007. All pathologic Gleason 7 cases were identified and assessed for quantity of Gleason pattern 4. Three methods were used to quantify the extent of Gleason 4: a quantitative Gleason score (qGS) based on the proportion of tumor composed of Gleason pattern 4, a size-weighted score (swGS) incorporating the overall quantity of Gleason 4, and a size index (siGS) incorporating the quantity of Gleason 4 based on the index lesion.
Associations between the above metrics and BCR were evaluated using Cox proportional hazards regression analysis.
qGS, swGS, and siGS were significantly associated with BCR on multivariate analysis when adjusted for traditional Gleason score, age, prostate specific antigen, surgical margin, and stage. Using Harrell's c-index to compare the scoring systems, qGS (0. 83), swGS (0. 84), and siGS (0. 84) all performed better than the traditional Gleason score (0. 82).
Quantitative measures of Gleason pattern 4 predict BCR better than the traditional Gleason score.
In men with Gleason 7 prostate cancer, quantitative analysis of the proportion of Gleason pattern 4 (quantitative Gleason score), as well as size-weighted measurement of Gleason 4 (size-weighted Gleason score), and a size-weighted measurement of Gleason 4 based on the largest tumor nodule significantly improve the predicted risk of biochemical recurrence compared with the traditional Gleason score.
European urology. 2015 Oct 30 [Epub ahead of print]
Fang-Ming Deng, Nicholas M Donin, Ruth Pe Benito, Jonathan Melamed, Julien Le Nobin, Ming Zhou, Sisi Ma, Jinhua Wang, Herbert Lepor
Department of Pathology, New York University School of Medicine, New York, NY, USA. , Department of Urology, Institute of Urologic Oncology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA. Department of Pathology, New York University School of Medicine, New York, NY, USA. , Department of Pathology, New York University School of Medicine, New York, NY, USA. , Department of Urology, New York University School of Medicine, New York, NY, USA. , Department of Pathology, New York University School of Medicine, New York, NY, USA; Department of Urology, New York University School of Medicine, New York, NY, USA. , Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA. , Center for Health Informatics and Bioinformatics, New York University School of Medicine, New York, NY, USA; NYU Cancer Institute, New York University School of Medicine, New York, NY, USA. , Department of Urology, New York University School of Medicine, New York, NY, USA.